Biotech Articles Latest News Trending News Sort By Last 24 Hours Last 3 Days Last 5 Days Last 7 Days Last 14 Days Last 30 Days Last 90 Days All Time Time Frame Keywords May 20, 2026 12:55 PM ETFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 OutlookLeo MillerNYSE:LLYNYSE:NVORead From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 OutlookMay 20, 2026 10:35 AM ETMirum Pharma: A Rare Disease Growth Story to WatchChris MarkochNASDAQ:MIRMRead Mirum Pharma: A Rare Disease Growth Story to WatchMay 15, 2026 5:05 AM ET2 Ways to Play the Big Pharma Patent CliffNathan ReiffNYSEARCA:XBINASDAQ:IBBNYSE:PFERead 2 Ways to Play the Big Pharma Patent CliffMay 7, 2026 8:05 AM ETWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsLeo MillerNYSE:LLYNYSE:NVONYSE:HIMSRead What the FDA's Latest Proposal Means for Lilly, Novo, and HimsMay 2, 2026 6:45 AM ETThe Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatJessica MitacekNYSE:ABBVNYSE:AZNNYSE:GSKRead The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatMay 1, 2026 11:05 AM ETLilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentNathan ReiffNYSE:LLYNYSE:NVORead Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentMay 1, 2026 8:45 AM ETViking Therapeutics Faces Timeline Risk—But Upside Could Be HugeChris MarkochNASDAQ:VKTXNYSE:LLYNYSE:NVORead Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeApril 29, 2026 12:50 PM ETAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Thomas HughesNYSE:ABBVNYSE:ABTRead AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?April 27, 2026 5:05 AM ET3 Biotech Stocks That Could Benefit from the Patent CliffChris MarkochNASDAQ:NTLANASDAQ:BEAMNASDAQ:CRSPRead 3 Biotech Stocks That Could Benefit from the Patent CliffApril 14, 2026 12:10 PM ETJohnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings ResultsThomas HughesNYSE:JNJRead Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings ResultsApril 9, 2026 12:00 PM ET3 Dividend Aristocrats Whose Yields Can Help Combat InflationChris MarkochNYSE:AMCRNYSE:CVXNYSE:ABBVRead 3 Dividend Aristocrats Whose Yields Can Help Combat InflationApril 2, 2026 10:15 AM ETLilly's Next Empire: A $10 Billion Bet on AI and NeuroscienceJeffrey Neal JohnsonNYSE:LLYRead Lilly's Next Empire: A $10 Billion Bet on AI and NeuroscienceMarch 31, 2026 5:58 AM ETMerck Just Made a Big Bet on a New Cancer Growth Engine Jessica MitacekNYSE:MRKNYSE:LLYNYSE:ABBVRead Merck Just Made a Big Bet on a New Cancer Growth Engine March 16, 2026 6:24 AM ETThe S&P 500's 3 Best-Performing Stocks So Far in 2026Ryan HassonNASDAQ:MRNANYSEARCA:SPYNASDAQ:SNDKRead The S&P 500's 3 Best-Performing Stocks So Far in 2026March 16, 2026 5:44 AM ET3 Companies at the Forefront of the GLP-1 Pill WarsNathan ReiffNYSE:LLYNASDAQ:VKTXNASDAQ:GPCRRead 3 Companies at the Forefront of the GLP-1 Pill WarsMarch 15, 2026 6:19 AM ETEli Lilly’s Employer Push Could Unlock New GLP-1 DemandLeo MillerNYSE:LLYNYSE:NVORead Eli Lilly’s Employer Push Could Unlock New GLP-1 DemandMarch 13, 2026 10:22 AM ETThe Real Reason Eli Lilly Is Pouring $3 Billion Into ChinaJeffrey Neal JohnsonNYSE:LLYNYSE:NVORead The Real Reason Eli Lilly Is Pouring $3 Billion Into ChinaMarch 12, 2026 1:24 PM ETWhy 2 Small Biotechs May Hold the Key to New Cancer TreatmentsNathan ReiffNASDAQ:IOVANASDAQ:IBRXRead Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsMarch 10, 2026 12:03 PM ETPatience Pays: Hims & Hers Surges on News of Novo Nordisk DealJordan ChusslerNYSE:HIMSNYSE:NVORead Patience Pays: Hims & Hers Surges on News of Novo Nordisk DealMarch 7, 2026 6:49 AM ET3 Undervalued Names Too Cheap to IgnoreNathan ReiffNYSE:MRKNASDAQ:CPBNYSE:USFDRead 3 Undervalued Names Too Cheap to IgnoreMarch 6, 2026 6:25 AM ETThese 3 Cash Flow Machines Provide Stability in Uncertain MarketsNathan ReiffNASDAQ:GILDNYSE:ABBVNYSE:VRead These 3 Cash Flow Machines Provide Stability in Uncertain MarketsFebruary 26, 2026 12:37 PM ETViking Therapeutics: The High-Stakes Weight Loss ContenderJeffrey Neal JohnsonNYSE:NVONYSE:LLYNASDAQ:VKTXRead Viking Therapeutics: The High-Stakes Weight Loss ContenderFebruary 24, 2026 2:37 PM ETBoring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorJeffrey Neal JohnsonNYSE:JNJRead Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector More Articles by TopicArticle TopicsAll ArticlesAIAnalyst RatingsBiotechCongressional TradingConsumer Discretionary SectorConsumer Staples SectorDefenseDividendEarningsElectric VehicleEnergy SectorETFFinance SectorHealthcare SectorIndustrial SectorInsider TradingIPOMacroMaterials SectorMergers & AcquisitionsQuantum ComputingRare Earth MineralsSemiconductorShort InterestSpaceStock IdeaStock MarketTechnology SectorUtilities SectorInstant Alert TopicsAll Instant AlertsAnalystCongressional TradesConsensusCorporate BuybackCorporate Event TranscriptStock ListDividendEarningsEarnings PreviewEarnings Transcript HighlightsEstimatesGuidanceInsider TradeLockup ExpirationMarketBeat List ArticlesOptionsPriceSEC FilingStock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.